Bradykinin receptor antagonists: Therapeutic implications

IDrugs

Volumn 6, Issue 6, 2003, Pages 581-586

  Sharma, Jagdish N ^a   Al Dhalmawi, Ghadeer ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Asthma; Bradykinin; Bradykinin antagonists; Bradykinin receptors; Cancer; Inflammation

Indexed keywords

BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B1 RECEPTOR NONPEPTIDE ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR NONPEPTIDE ANTAGONIST; BRADYKININ DERIVATIVE; BRADYKININ NONPEPTIDE ANTAGONIST; BRADYKININ PEPTIDE ANTAGONIST; BRADYKININ RECEPTOR AGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; JMV 1640; PLASMA KALLIKREIN; SSR 240612; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; CANCER; CARDIOVASCULAR EFFECT; CHRONIC INFLAMMATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; ENTERITIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; KALLIKREIN KININ SYSTEM; LIVER CIRRHOSIS; NONHUMAN; PAIN; PATHOLOGY; PHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR AFFINITY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH ACID SECRETION; TREATMENT CONTRAINDICATION;

ASTHMA; HUMANS; INFLAMMATION; NEOPLASMS; OLIGOPEPTIDES; PAIN; RECEPTORS, BRADYKININ;

EID: 0038354974     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Sharma JN: Kinin-forming system in the genesis of hypertension. Agents Actions (1984) 14(2):200-205.
2. Sharma JN: Interrelationship between the kallikrein-kinin system and hypertension. Gen Pharmacol (1988) 19(2):177-187.
3. Sharma JN: Kinin system and prostaglandins in the intestine. Pharmacol Toxicol (1988) 63(5):310-316.
4. Erdos EG: Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol (1990) 15(Suppl 6):S20-S24.
5. Sharma JN. Involvement of the kinin-forming system in the physiopathology of rheumatoid inflammation. Agents Actions Suppl (1992) 38(Pt 3):343-361.
6. Sharma JN, Mohsin SS: The role of chemical mediators in the pathogenesis of inflammation with emphasis on the kinin system. Exp Pathol (1990) 38(2):73-96.
7. Sharma JN: Therapeutic prospects of bradykinin receptor antagonists. Gen Pharmacol (1993) 24(2):267-274.
8. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev (1992) 44(1):1-80.
9. Vavrek RJ, Sterwart JM: Competitive antagonists of bradykinin. Peptides (1985) 6(2):161-164.
10. Regoli D, Barabe J, Park WK: Receptors for bradykinin in rabbit aortae. Can J Physiol Pharmacol (1977) 55(4):855-867.
11. Sharma JN, Buchanan WW: Pathogenic responses of bradykinin system in chronic inflammatory rheumatoid disease. Exp Toxicol Pathol (1994) 46(6):421-433.
12. Takagaki Y, Kitamura N, Nakanishi S: Cloning and sequence analysis of cDNAs for human high molecular weight and low molecular weight prekininogens. Primary structures of two human prekininogens. J Biol Chem (1985) 260(14):8601-8609.
13. Nagayasu T, Nagasawa S: Studies of human kininogen. Identification, characterization, and cleavage by plasma kallikrein of high molecular weight (HMW) kininogen. J Biochem (1979) 85(1):249-258.
14. Green LM: T-kinin and T-kininogen: Children of new technology. Biochem Pharmacol (1984) 33(19):2943-2944.
15. Nustad K, Vaaje K, Pierce JV: Synthesis of kallikrein by rat kidney slices. Br J Pharmacol (1975) 53(2):229-234.
16. Britos J, Nolly HL: Kinin-forming enzyme of rat cardiac tissue. Subcellular distribution and biochemical properties. Hypertension (1981) 3(6 Pt 2):42-45.
17. Sharma JN, Zeitlin IJ, Deodhar SD, Buchanan WW: Detection of kallikrein-like activity in inflamed synovial tissue. Arch Int Pharmacodyn Ther (1983) 262(2):279-286.
18. Sharma JN, Wirth KJ: Inhibition of rat adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikrein. Gen Pharmacol (1996) 27(1):133-136.
19. Cassim B, Mody G, Bhoola K: Kallikrein cascade and cytokines in inflamed joints. Pharmacol Ther (2002) 94(1-2):1-34. Review on bradykinins, cytokines and rheumatoid arthritis.
20. Takada Y, Skidgel RA, Erdos EG: Purification of human urinary prokallikrein: Identification of the site of activation by metaliproteinase thermolysin. Biochem J (1985) 232(3):851-858.
21. Weiss AS, Gallin JL, Kaplan AP: Fletcher factor deficiency: A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity and kinin generation. J Clin Invest (1974) 53(2):622-633.
22. Cochrane CG, Revak SD, Wuepper D: Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med (1973) 138(6):1564-1583.
23. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev (1980) 32(1):1-46.
24. Mahabeer R, Bhoola KD: Kallikrein and kinin receptor genes. Pharmacol Ther (2000) 88(1):77-89.
25. 3 bradykinin receptor. Mol Pharmacol (1989) 36(1):1-8.
26. Altamura M, Meini S, Quartara L, Maggi CA: Nonpeptide antagonists for kinin receptors. Regul Pept (1999) 80(1-2):13-26.
27. 1 receptors. A review. Immunopharmacology (1995) 30(1):1-26.
28. 1 receptors for kinin. Pharmacol Rev (1998) 50(3):357-386.
29. 2 receptor characterization. Trends Pharmacol Sci (1990) 11(4):156-161.
30. 1 receptor and its role of pathophysiology.
31. Hess JF, Borkowski JA, Stonesifer GY, MacNeil T, Strader CD, Ranson RW: Cloning and pharmacological characterization of bradykinin receptors. Braz J Med Biol Res (1994) 27(8):1725-1731.
32. Walden PD, Lefkowitz GK, Ittmann M, Lepor H, Monaco ME: Mitogen activation of human prostate-derived fibromuscular stromal cells by bradykinin. Br J Pharmacol (1999) 127(1):220-226.
33. 2 receptors in target cells of kinin action. Visualization of the receptor protein in A431 cells, neutrophils and kidney sections. Braz J Med Biol Res (1994) 27(8):1739-1756.
34. Regoli D, Rhaleb NE, Drapeau G, Dion S, Tousignant C, D'Orleans-Juste P, Devillier P: Basic pharmacology of kinins: Pharmacologic receptors and other mechanisms. Adv Exp Med Biol (1989) 247A:399-407.
35. Couture R, Harrisson M, Vianna RM, Cloutier F: Kinin receptors in pain and inflammation. Eur J Pharmacol (2001) 429(1-3):161-176.
36. 2 receptor is activated by kallikrein and other serine proteases. Mol Pharmacol (2000) 58(4):828-836.
37. 2 receptor localization and expression in the hypothalmo-pituitary-adrenal axis of spontaneously hypertensive rats. Int Immunopharmacol (2003) 3(3):285-292.
38. Alzamora AC, Ferreira PM, De Oliveira CN, Alzamora F, Vieira MA: Kinin receptors mediating the effect of bradykinin on gastric acid secretion. Regul Pept (1998) 73(2):113-117.
39. O'Connor BJ, Crowther SD, Costello JF, Morley J: Selective airway responsiveness in asthma. Trends Pharmacol Sci (1999) 20(1):9-11.
40. Lee KL, Villereal ML: Tyrosine phosphorylation and activation of pp60c-src and pp125FAK in bradykinin-stimulated fibroblasts. Am J Physiol (1996) 270 (5 Pt 1):C1430-C1437.
41. Cox R: Medicinal Chemistry - 28th National Symposium (Part II) - Overnight Report, San Diego, CA, USA. Iddb Meeting Report (2002) June 8-12.
42. Bedos P, Amblad M, Subra G, Dodey P, Luccarini JM, Paquet JL, Pruneau D, Aumelas A, Martinez J: A rational approach to the design and synthesis of a new bradykinin B1 receptor antagonist. J Med Chem (2000) 43(12):2387-2394.
43. Aventis Pharma AG: Aventis Pharma and Jerini sign development and licensing agreement for the compound Icatibant. Press Release (2001) November 16.
44. Kim JJ, Wood MR, DiPardo RM, Dorsey BD, Han W, Ransom RW, Murphy KL, Harrell CM, Chang RSL, Miller PJ, O'Malley SS et al: Benzodiazepines as potent and selective bradykinin B1 receptor antagonists. 225th American Chemical Society, New Orleans, LA, USA (2003): MEDI 202.
45. Sanofi Synthélabo: Financial Analysts Meeting: Information meeting - September 2 & 3, 2002. Company Presentation (2002) September 2-3.